top of page
PRESS
Positive Outcome of FDA Pre-IND Meeting for KAND567
San Francisco, June 5, 2025 - Recardio Inc., a late stage clinical stage life science company developing therapies for cardiovascular and...
Jun 52 min read
83 views
Newly Granted Patent Application improves Patient Compliance
San Francisco, May 27, 2025 - Recardio Inc., a late stage clinical stage life science company developing therapies for cardiovascular and...
May 272 min read
34 views
Recardio signs letter of intent with Kancera for licensing of cardiometabolic assets
San Francisco, March 7, 2025 - Recardio Inc., a late clinical-stage life science company developing therapies for cardiovascular and...
Mar 73 min read
385 views
bottom of page